--- title: Biograil raises €20 Million financing round date: 2026-11-04T08:00:00Z modified: 2026-11-04T07:28:15Z permalink: "https://www.htgf.de/en/biograil-raises-20-million-financing-round/" type: post status: publish excerpt: "" wpid: 134456 categories: - News - Press language: - English timestamp: 2026-11-04T07:28:15Z tags: - News - Press - English --- # **Biograil raises €20 Million financing round to advance preparations for clinical trials** Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics that would otherwise have to be injected, announced the closure of a EUR 20 million financing round. Verve Ventures and Megatrend Invest are backing the company, HTGF, which led Biograil’s seed syndicate in 2019, is participating through its HTGF Opportunity growth fund. The additional funds will support the ongoing activities for the planned phase 1 clinical testing of BIONDD® to achieve key milestones such as non-clinical GLP studies and establish manufacturing GMP process prior to a larger financing in 2027. **Karsten Lindhardt, CEO of Biograil:** “Excellent to see such strong support from existing internal investors and involve the HTGF Opportunity growth fund in the round. This, in combination with non-diluting funding from partnerships, will enable Biograil to continue to move our BIONDD® technology toward Phase 1 clinical studies. The BIONDD® technology can allow oral delivery of large market compounds for better convenience and medical benefit and in addition create development opportunities for new innovative combination products which may never have been feasible or attractive as conventional injectable or oral products”. **Anke Caßing, Principal at HTGF:** “We first invested in Biograil in 2019 because we saw the potential of its approach to oral drug delivery. Our participation through the HTGF Opportunity reflects our continued conviction in that potential as the company prepares for clinical development.” **About Biograil ApS** Biograil is a Copenhagen based biotech company developing pharmaceutical products based upon the BIONDD® device contained in a standard size, double zero or single zero, capsule able to deliver active therapeutics into the stomach mucosal wall to be effectively distributed in the human body. Such therapeutics can be currently marketed products, including multi-billion-dollar injectable pharmaceuticals or new chemical entities that cannot otherwise be delivered orally. The Biograil device uses a novel mechanism to facilitate the delivery of active substances, i.e., biologics, efficiently into the stomach wall utilizing a proprietary platform technology manufactured by injection molding. The team behind Biograil is a combination of seasoned entrepreneurs with extensive experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA. The Biograil investor syndicate includes Megatrend Invest, Verve Ventures, High-Tech Gründerfonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capital, Anobis GmbH and Roquette Ventures. **About Verve Ventures** Verve Ventures is one of Europe’s most active deep tech investors. Founded in Switzerland in 2010, Verve backs science-driven founders from Seed onward across health & bio, energy & resources, and computing & AI infrastructure. With more than CHF 400 million in assets under management, Verve has achieved 30+ exits to global leaders including Apple, Ipsen, Ripple and EssilorLuxottica. **About HTGF – High-Tech Gründerfonds** Germany and Europe need a New Wirtschaftswunder, we are laying the foundations. ​We are Germany’s most active VC investor, funding deep-tech, life sciences and digital tech companies that secure technological sovereignty and build industrial strength. From the initial idea through to international scaling, we support bold founders as a multi-stage VC platform – seamlessly, reliably and for the long term. 350 active start-ups, 200+ exits and 5 unicorns. Over €10 billion in follow-on funding mobilised.​ Together with DTCF, we represent more than €3 billion in fund volume – and turn German and European innovations into global tech champions.​ Investors in the HTGF Opportunity growth fund include the ERP Special Fund and KfW with the resources of the Zukunftsfonds (“Future Fund”). Further information can be found at [HTGF.de](https://www.htgf.de/de/) or on [LinkedIn](https://de.linkedin.com/company/high-tech-gruenderfonds) and on the [Zukunftsfonds](https://www.bundeswirtschaftsministerium.de/Redaktion/EN/Artikel/Economy/future-fund.html) page.